Bank of Nova Scotia Buys 21,133 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Bank of Nova Scotia raised its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 66.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,927 shares of the medical research company's stock after acquiring an additional 21,133 shares during the quarter. Bank of Nova Scotia's holdings in IQVIA were worth $10,404,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Synergy Asset Management LLC bought a new stake in shares of IQVIA in the 4th quarter valued at about $33,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA during the 4th quarter worth about $44,000. Zions Bancorporation N.A. lifted its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares in the last quarter. Versant Capital Management Inc lifted its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after purchasing an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA in the fourth quarter worth $60,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 0.8 %

IQV traded up $1.23 on Wednesday, reaching $150.38. The company's stock had a trading volume of 358,721 shares, compared to its average volume of 1,387,154. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business's 50 day moving average is $180.02 and its 200 day moving average is $198.45. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The stock has a market cap of $26.51 billion, a price-to-earnings ratio of 20.05, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IQV shares. Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. BTIG Research downgraded IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. Finally, Citigroup dropped their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $241.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.